EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a neuraminidase specific influenza a virus vaccine in children antibody responses and effects on 2 successive outbreaks of natural infection


Journal of Infectious Diseases 140(6): 844-850
Evaluation of a neuraminidase specific influenza a virus vaccine in children antibody responses and effects on 2 successive outbreaks of natural infection
Three groups of children were immunized with an inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A), a neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B) or a placebo. Immunization induced seroconversion for H3Ch- and N2Ch-specific antibody in group A and for N2Ch antibody in group B. The protective efficacies observed against naturally acquired illness with the Port Chalmers strain of influenza A virus were 68.7% and 37.4% in groups A and B, respectively, in comparison to the placebo group and those against illness produced by the subsequent outbreak of the Victoria strain were 80.0% and 72.7%. Neuraminidase-specific immunization may play a role in protection against influenza. Although the degree of protection after vaccination with the Heq1N2Ch vaccine was less than that provided by the biphasic H3ChN2Ch vaccine against the Port Chalmers strain, it appeared similar in the 2 vaccine study groups against the Victoria strain.


Accession: 005395312



Related references

Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. Journal of Infectious Diseases 140(6): 844-850, 1979

Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clinical and Diagnostic Laboratory Immunology 3(5): 511-516, 1996

Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type. Vaccine 34(33): 3773-3779, 2016

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 26(33): 4210-4217, 2008

Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. Journal of Infectious Diseases 135(4): 499-506, 1977

Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine 21(1-2): 60-66, 2002

Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine 21(1-2): 60-66, 2002

Antibody responses in humans to influenza virus type b host cell derived variants after vaccination with standard egg derived vaccine or natural infection. Journal of Clinical Microbiology 26(2): 333-337, 1988

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. Journal of Infectious Diseases 154(1): 121-127, 1986

Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. Journal of Infectious Diseases 134(4): 384-394, 1976